These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor. Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390 [TBL] [Abstract][Full Text] [Related]
23. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis. Giberson M; Mourad A; Gniadecki R Dermatology; 2017; 233(4):320-325. PubMed ID: 29169156 [TBL] [Abstract][Full Text] [Related]
24. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Querfeld C; Scarisbrick JJ; Assaf C; Guenova E; Bagot M; Ortiz-Romero PL; Quaglino P; Bonizzoni E; Hodak E Dermatology; 2022; 238(2):347-357. PubMed ID: 34091453 [TBL] [Abstract][Full Text] [Related]
25. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. van Doorn R; Van Haselen CW; van Voorst Vader PC; Geerts ML; Heule F; de Rie M; Steijlen PM; Dekker SK; van Vloten WA; Willemze R Arch Dermatol; 2000 Apr; 136(4):504-10. PubMed ID: 10768649 [TBL] [Abstract][Full Text] [Related]
26. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. Abbott RA; Sahni D; Robson A; Agar N; Whittaker S; Scarisbrick JJ J Am Acad Dermatol; 2011 Aug; 65(2):313-319. PubMed ID: 21529998 [TBL] [Abstract][Full Text] [Related]
27. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. van Santen S; van Doorn R; Neelis KJ; Daniëls LA; Horváth B; Bruijn MS; Sanders CJG; van Rossum MM; de Haas ERM; Veraart JCJM; Bekkenk MW; Vermeer MH; Willemze R Br J Dermatol; 2017 Jul; 177(1):223-228. PubMed ID: 28132406 [TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880 [TBL] [Abstract][Full Text] [Related]
29. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Doerschner M; Pekar-Lukacs A; Messerli-Odermatt O; Dommann-Scherrer C; Rütti M; Müller AM; Nair G; Kamarachev J; Kerl K; Beer M; Messerli M; Frauenknecht K; Haralambieva E; Hoetzenecker W; French LE; Guenova E Br J Dermatol; 2019 Dec; 181(6):1296-1302. PubMed ID: 30565216 [TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Talpur R; Singh L; Daulat S; Liu P; Seyfer S; Trynosky T; Wei W; Duvic M Clin Cancer Res; 2012 Sep; 18(18):5051-60. PubMed ID: 22850569 [TBL] [Abstract][Full Text] [Related]
31. Prognostic indicators for mycosis fungoides in a Greek population. Nikolaou V; Papadavid E; Patsatsi A; Siakantaris M; Economidi A; Marinos L; Koletsa T; Georgiou E; Pappa V; Stratigos A; Antoniou C Br J Dermatol; 2017 May; 176(5):1321-1330. PubMed ID: 27552962 [TBL] [Abstract][Full Text] [Related]